caa a22 4500 605543666 CHVBK 20210128100927.0 cr unu---uuuuu 210128e20150401xx s 000 0 eng 10.1007/s00109-014-1228-0 doi (NATIONALLICENCE)springer-10.1007/s00109-014-1228-0 Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc [Elektronische Daten] [Yaxi Ma, Handi Cao, Siyue Lou, Xuejing Shao, Wen Lv, Xiaotian Qi, Yujia Liu, Meidan Ying, Qiaojun He, Xiaochun Yang] Springer-Verlag Berlin Heidelberg, 2014 Aurora B nationallicence c-Myc nationallicence Cisplatin nationallicence Chemotherapy resistance nationallicence Ovarian carcinoma nationallicence Drug in combination nationallicence Ma Yaxi Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, China aut Cao Handi Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut Lou Siyue Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut Shao Xuejing Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut Lv Wen Tongde Hospital of Zhejiang Province, 310009, Hangzhou, China aut Qi Xiaotian Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut Liu Yujia Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut Ying Meidan Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut He Qiaojun Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut Yang Xiaochun Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut Journal of Molecular Medicine Springer Berlin Heidelberg 93/4(2015-04-01), 427-438 0946-2716 93:4<427 2015 93 109 https://doi.org/10.1007/s00109-014-1228-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00109-014-1228-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ma Yaxi Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, China aut NATIONALLICENCE 700 1- Cao Handi Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut NATIONALLICENCE 700 1- Lou Siyue Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut NATIONALLICENCE 700 1- Shao Xuejing Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut NATIONALLICENCE 700 1- Lv Wen Tongde Hospital of Zhejiang Province, 310009, Hangzhou, China aut NATIONALLICENCE 700 1- Qi Xiaotian Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut NATIONALLICENCE 700 1- Liu Yujia Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut NATIONALLICENCE 700 1- Ying Meidan Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut NATIONALLICENCE 700 1- He Qiaojun Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut NATIONALLICENCE 700 1- Yang Xiaochun Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China aut NATIONALLICENCE 773 0- Journal of Molecular Medicine Springer Berlin Heidelberg 93/4(2015-04-01), 427-438 0946-2716 93:4<427 2015 93 109